Phase Ib/II Randomized Clinical Trial of Chemotherapy With Nab-paclitaxel/Gemcitabine/Cisplatin +/- the AXL-inhibitor Bemcentinib for Patients With Metastatic Pancreatic Cancer
Summary
The purpose of this phase Ib/II trial is to evaluate the safety and efficacy of nab-paclitaxel with gemcitabine and cisplatin with or without bemcentinib (BGB324) in patients with metastatic pancreatic cancer.
General Information
NCT#: NCT03649321
Study ID: STU 062018-024
Trial Phase: Phase I/II
Trial Sponsor: Translational Genomics Research Institute (TGen), University of Texas Southwestern Medical Center, BerGenBio
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Cisplatin, Bemcentinib